Come Monday, GSK and consumer health unit Haleon will officially part ways, leaving the Big Pharma's biopharma and vaccines divisions to stand on their own. This will give the drugmaker—and its CEO Emma Walmsley—a chance to prove themselves after a long period of questioning from some market watchers and investors.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,